Your browser doesn't support javascript.
The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper.
Gerotziafas, Grigoris T; Catalano, Mariella; Theodorou, Yiannis; Dreden, Patrick Van; Marechal, Vincent; Spyropoulos, Alex C; Carter, Charles; Jabeen, Nusrat; Harenberg, Job; Elalamy, Ismail; Falanga, Anna; Fareed, Jawed; Agathaggelou, Petros; Antic, Darko; Antignani, Pier Luigi; Bosch, Manuel Monreal; Brenner, Benjamin; Chekhonin, Vladimir; Colgan, Mary-Paula; Dimopoulos, Meletios-Athanasios; Douketis, Jim; Elnazar, Essam Abo; Farkas, Katalin; Fazeli, Bahare; Fowkes, Gerry; Gu, Yongquan; Gligorov, Joseph; Ligocki, Mark A; Indran, Tishya; Kannan, Meganathan; Kantarcioglu, Bulent; Kasse, Abdoul Aziz; Konstantinidis, Kostantinos; Leivano, Fabio; Lewis, Joseph; Makatsariya, Alexander; Mbaye, P Massamba; Mahé, Isabelle; Panovska-Stavridis, Irina; Olinic, Dan-Mircea; Papageorgiou, Chryssa; Pecsvarady, Zsolt; Pillon, Sergio; Ramacciotti, Eduardo; Abdel-Razeq, Hikmat; Sabbah, Michele; Sassi, Mouna; Schernthaner, Gerit; Siddiqui, Fakiha; Shiomura, Jin.
  • Gerotziafas GT; Sorbonne Université, INSERM, UMR_S 938, Research Group Cancer, Biology and Therapeutics, Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France.
  • Catalano M; Thrombosis Center, Tenon-Saint Antoine, Hôpitaux Universitaires de l'Est Parisien, Assistance Publique Hôpitaux de Paris (APHP), France.
  • Theodorou Y; Research Center on Vascular Disease & Angiology Unit, Department of Biomedical Science, L Sacco Hospital, University of Milan, Milan, Italy.
  • Dreden PV; Centre d'Immunologie et des Maladies Infectieuses UPMC UMRS CR7, Inserm U1135, CNRS ERL 8255, Paris, France.
  • Marechal V; Sorbonne Université, INSERM, UMR_S 938, Research Group Cancer, Biology and Therapeutics, Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France.
  • Spyropoulos AC; Sorbonne Université, INSERM, UMR_S 938, Research Group Cancer, Biology and Therapeutics, Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France.
  • Carter C; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, United States.
  • Jabeen N; Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
  • Harenberg J; Department of Clinical Research, College of Pharmacy & Health Sciences, Campbell University, Buies Creek, North Carolina, United States.
  • Elalamy I; Department of Microbiology, University of Karachi, Karachi, Pakistan.
  • Falanga A; Department for Physical Chemistry, Heidelberg University, Heidelberg, Germany.
  • Fareed J; DOASENSE GmbH, Heidelberg, Germany.
  • Agathaggelou P; Sorbonne Université, INSERM, UMR_S 938, Research Group Cancer, Biology and Therapeutics, Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France.
  • Antic D; Thrombosis Center, Tenon-Saint Antoine, Hôpitaux Universitaires de l'Est Parisien, Assistance Publique Hôpitaux de Paris (APHP), France.
  • Antignani PL; Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
  • Bosch MM; Immunohematology and Transfusion Medicine Department, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Brenner B; School of Medicine, University of Milan Bicocca, Monza, Italy.
  • Chekhonin V; Department of Pathology and Laboratory Medicine, Cardiovascular Research Institute, Health Sciences Division, Loyola University Chicago, Maywood, Illinois, United States.
  • Colgan MP; Department of Pharmacology and Neuroscience, Cardiovascular Research Institute, Health Sciences Division, Loyola University Chicago, Maywood, Illinois, United States.
  • Dimopoulos MA; Cyprus Department of Interventional Cardiology, American Heart Institute of Cyprus, Nicosia, Cyprus.
  • Douketis J; Clinic of Hematology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Elnazar EA; Vascular Center, Nuova Villa Claudia, Rome, Italy.
  • Farkas K; Department of Internal Medicine, Hospital Universitario Germans Trias i Pujol de Badalona, Universidad Católica de Murcia, Murcia, Spain.
  • Fazeli B; Thrombosis and Hemostasis Unit, Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
  • Fowkes G; Bruce Rappaport Faculty of Medicine, The Technion-Israel Institute of Technology, Haifa, Israel.
  • Gu Y; Department of Fundamental and Applied Neurobiology, V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation, Moscow, Russia.
  • Gligorov J; Department of Vascular Surgery, St. James's Hospital/Trinity College Dublin, Dublin, Ireland.
  • Ligocki MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Indran T; Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Kannan M; Division of Thoracic Surgery, St. Joseph's Healthcare Hamilton, Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada.
  • Kantarcioglu B; Department of Surgery, Ministry of Health, Saudi Arabia.
  • Kasse AA; Department of Angiology, St. Imre University Teaching Hospital, Budapest, Hungary.
  • Konstantinidis K; Immunology Department, Avicenna (Bu-Ali) Research Institute, Mashhad University of Medical Sciences, Iran.
  • Leivano F; Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom.
  • Lewis J; Department of Vascular Surgery, Xuan Wu Hospital, Capital Medical University and Institute of Vascular Surgery, Capital Medical University, Beijing, China.
  • Makatsariya A; Sorbonne Université, INSERM, UMR_S 938, Research Group Cancer, Biology and Therapeutics, Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France.
  • Mbaye PM; Medical Oncology Department, CLIP(2) Galilée, Hôpital Tenon, Hôpitaux Universitaires de l'Est Parisien, Assistance Publique Hôpitaux de Paris (APHP), France.
  • Mahé I; Department of Pathology and Laboratory Medicine, Cardiovascular Research Institute, Health Sciences Division, Loyola University Chicago, Maywood, Illinois, United States.
  • Panovska-Stavridis I; Department of Pharmacology and Neuroscience, Cardiovascular Research Institute, Health Sciences Division, Loyola University Chicago, Maywood, Illinois, United States.
  • Olinic DM; Australia Department of Haematology, Monash Health, Clayton, Victoria, Australia.
  • Papageorgiou C; Division of Blood and Vascular Biology, Department of Life Sciences, School of Life Sciences, Central University of Tamil Nadu, Thiruvarur, India.
  • Pecsvarady Z; Department of Hematology, Okmeydani Training and Research Hospital, Istanbul, Turkey.
  • Pillon S; Institut du Cancer UCAD, Centre International de Cancérologie de Dakar, Dakar, Senegal.
  • Ramacciotti E; 5th Surgical Department, Group of Vascular Surgery, Hippokrateio General University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Abdel-Razeq H; Department of Pharmacology and Neuroscience, Cardiovascular Research Institute, Health Sciences Division, Loyola University Chicago, Maywood, Illinois, United States.
  • Sabbah M; Department of Surgery, Stony Brook Southampton Hospital, Southampton, New York, United States.
  • Sassi M; Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
  • Schernthaner G; Université Virtuelle du Sénégal, Dakar, Senegal.
  • Siddiqui F; Innovative Therapies in Haemostasis, Hôpital Louis Mourier, APHP, Colombes, Université de Paris, INSERM, F-75006 Paris, France.
  • Shiomura J; University Clinic of Hematology, Skopje, Republic of North Macedonia.
Thromb Haemost ; 121(8): 992-1007, 2021 08.
Article in English | MEDLINE | ID: covidwho-1320246
ABSTRACT

BACKGROUND:

One year after the declaration of the coronavirus disease 2019 (COVID-19) pandemic by the World Health Organization (WHO) and despite the implementation of mandatory physical barriers and social distancing, humanity remains challenged by a long-lasting and devastating public health crisis. MANAGEMENT Non-pharmacological interventions (NPIs) are efficient mitigation strategies. The success of these NPIs is dependent on the approval and commitment of the population. The launch of a mass vaccination program in many countries in late December 2020 with mRNA vaccines, adenovirus-based vaccines, and inactivated virus vaccines has generated hope for the end of the pandemic. CURRENT ISSUES The continuous appearance of new pathogenic viral strains and the ability of vaccines to prevent infection and transmission raise important concerns as we try to achieve community immunity against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and its variants. The need of a second and even third generation of vaccines has already been acknowledged by the WHO and governments. PERSPECTIVES There is a critical and urgent need for a balanced and integrated strategy for the management of the COVID-19 outbreaks organized on three axes (1) Prevention of the SARS-CoV-2 infection, (2) Detection and early diagnosis of patients at risk of disease worsening, and (3) Anticipation of medical care (PDA).

CONCLUSION:

The "PDA strategy" integrated into state policy for the support and expansion of health systems and introduction of digital organizations (i.e., telemedicine, e-Health, artificial intelligence, and machine-learning technology) is of major importance for the preservation of citizens' health and life world-wide.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Public Health / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid / Vaccines / Variants Limits: Humans Language: English Journal: Thromb Haemost Year: 2021 Document Type: Article Affiliation country: A-1535-8807

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Public Health / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid / Vaccines / Variants Limits: Humans Language: English Journal: Thromb Haemost Year: 2021 Document Type: Article Affiliation country: A-1535-8807